Стоперан

Quick links to important sections

Стоперан

Selected form

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Стоперан

Quick Facts

Property Description
Active ingredient Loperamide hydrochloride
Form Oral capsules, tablets, liquid
Pharmacological class Antidiarrheal Agent (Antiperistaltic)
General purpose Reducing frequency of loose bowel movements
Origin Synthetic opioid derivative

What Type of Medicine is Стоперан? (Loperamide Identity and Class)

Стоперан is a pharmaceutical product containing the active ingredient Loperamide hydrochloride, which is fundamentally classified as an Antidiarrheal Agent. The compound is a synthetic phenylpiperidine opioid derivative. This means the core chemical structure is laboratory-synthesized and specifically designed to interact with receptors primarily located in the gut.

Unlike certain systemic opioids, Loperamide is chemically engineered to act almost exclusively on the peripheral nervous system within the intestinal wall, minimizing effects on the central nervous system at standard therapeutic levels. The active substance is used in managing the symptoms of acute, non-specific diarrhea.

Composition and Available Pharmaceutical Forms

The core composition of Стоперан is its single-ingredient active substance, Loperamide hydrochloride. This single-focus formulation is compounded with standard pharmaceutical excipients (such as fillers and binders) necessary for creating stable products for oral administration. The medication is typically supplied in several established oral dosage forms, which include capsules, tablets, or sometimes an oral solution or liquid. The product is often positioned as an accessible option for managing sudden episodes of diarrhea.

General Purpose and Mechanism

The primary purpose of Стоперан is to provide symptomatic relief by regulating the pace of intestinal movement. It achieves this by binding to opioid receptors in the gut wall, which directly reduces the frequency and intensity of muscle contractions responsible for passing waste (propulsive peristalsis).

This anti-motility effect prolongs the transit time of materials through the bowel. This physiological adjustment allows the intestinal lining a greater opportunity to reabsorb essential water and electrolytes. The overall benefit is the reduction in the frequency and urgency of loose bowel movements, aiding in the normalization of stool consistency.

What side effects are possible with Стоперан?

Possible side effects and safety information

The safety profile of Loperamide hydrochloride is officially classified according to the frequency and body system affected, as documented in regulatory sources like the Summary of Product Characteristics (SmPC) and FDA labeling.

Frequency-Classified Reactions

The most frequently reported adverse drug reactions are concentrated in the gastrointestinal and nervous systems:

Classification Examples of Adverse Reactions (SOC)
Common (1%) Constipation, Flatulence, Headache, Nausea, Dizziness
Uncommon (0.1% to 1%) Abdominal pain/discomfort, Vomiting, Somnolence (drowsiness), Rash
Rare (< 0.1%) Ileus, Toxic Megacolon, Bullous eruptions, Anaphylactic shock
Not Known (Post-marketing) QT/QTc prolongation, Torsades de Pointes, Cardiac arrest

Serious Adverse Reactions and Safety Constraints

Official labeling documents rare but serious adverse reactions, which define specific limitations on the medicine's use. These include Toxic Megacolon and Paralytic Ileus, requiring immediate treatment cessation if symptoms such as abdominal distention or constipation develop. The medicine is contraindicated in children under two years of age. Serious cardiac events, including QT interval prolongation and Cardiac arrest, have been primarily associated with use exceeding recommended dosages, though these are listed among the rare and post-marketing reports in the official safety documents. Caution is advised in patients with hepatic impairment due to the increased risk of systemic exposure and Central Nervous System (CNS) toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Стоперан (Loperamide hydrochloride) can lead to serious, potentially life-threatening clinical manifestations documented in official regulatory labeling. Overdose typically presents as severe Central Nervous System (CNS) depression, including signs such as stupor, somnolence, miosis (pinpoint pupils), and respiratory depression. Regulator-documented severe outcomes center on cardiotoxicity, which may include prolongation of the QT/QTc and QRS intervals, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, and sudden death. Gastrointestinal signs of overdose include severe constipation and paralytic ileus.

Immediate Medical Attention is Required

Official regulatory guidance mandates that patients or caregivers seek immediate medical attention for any signs of severe overdose, particularly fainting, irregular heart rhythm, rapid heartbeat, or unresponsiveness. It is also mandated to contact a Poison Control Center right away.

Overdose Management

The opioid antagonist Naloxone is available as an antidote for CNS effects; however, repeated treatment may be necessary due to the drug's extended duration of action. Symptomatic and supportive treatment is required. Due to the risk of recurring CNS depression, close patient monitoring for at least 48 hours is necessary. Specific population-related warnings note that pediatric patients less than 2 years of age and patients with hepatic dysfunction are highly susceptible to severe CNS and cardiac adverse reactions.

Therapeutic Uses of Стоперан

Стоперан plays a role in managing symptoms related to physical discomfort and heightened physiological activity. It is applied across domains where additional symptomatic support is needed to help patients manage sudden discomfort and supports general well-being during symptomatic phases.

The medication is applied across several therapeutic areas. It is relevant for managing conditions presenting with acute episodes, recurrent or episodic manifestations, and situations involving transient functional strain, such as traveler's diarrhea.

Main Uses and Therapeutic Benefits

Стоперан is considered relevant in clinical settings requiring temporary assistance in symptom stabilization and is applicable in conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may appear suddenly, offering relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

This supportive use helps ease the overall symptom burden and contributes to easing discomfort during periods of heightened symptoms. The therapeutic benefit is relevant for easing patient discomfort during acute, self-limiting episodes, chronic conditions presenting with symptoms, and specific issues like traveler's diarrhea.


Quick Fact: Relief for Acute Diarrheal Symptoms

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility for Стоперан (Loperamide)

Official regulatory information strictly defines which populations are eligible to use Стоперан.

Contraindicated Populations

Use is contraindicated (absolutely forbidden) for patients with a known hypersensitivity to loperamide hydrochloride or any excipient, and in children less than 2 years of age. The medicine must also not be used in patients presenting with specific gastrointestinal conditions, including acute dysentery (diarrhea with fever and blood in stool), acute ulcerative colitis, pseudomembranous colitis associated with antibiotics, or when inhibition of peristalsis carries the risk of toxic megacolon.

Age and Condition Restrictions

Adults and adolescents 12 years and over are approved for standard use, while use in children aged 2 to 12 years is generally restricted or requires a clinician’s direction. Older adults do not require a dose adjustment. Caution is required for patients with hepatic impairment due to the risk of increased systemic exposure. Use during pregnancy and lactation is not recommended as safety has not been fully established, advising professional consultation.

Populations Permitted for Use

Use is generally permitted for adults, adolescents, older adults, and patients with renal impairment, where no dose adjustment is required.

What should I know about interactions with other medicines?

The interaction profile for Стоперан (Loperamide) is defined by official classifications addressing both pharmacokinetic and pharmacodynamic interactions.

Classification Description of Official Outcome
Exposure-Modifying Interactions Co-administration with strong inhibitors of P-glycoprotein (P-gp), CYP3A4, or CYP2C8 significantly increases Стоперан's plasma concentrations due to reduced clearance (e.g., Ketoconazole approx 5-fold, Itraconazole approx 3- to 4-fold, Quinidine, Ritonavir, or Gemfibrozil approx 2- to 3-fold).
Pharmacodynamic Interactions Combinations with other QT-prolonging medicines (e.g., Amiodarone, Moxifloxacin) must be avoided due to the documented risk of additive cardiotoxicity. Co-administration with CNS depressants or alcohol may increase the risk of profound sedation or central nervous system effects.

The regulatory structure requires that patients with hepatic impairment use the drug with caution, as reduced first-pass metabolism increases the risk of elevated exposure and associated CNS toxicity from accumulation. Elderly patients are also noted as potentially more susceptible to QTc interval prolongation effects from interacting drugs. Additionally, Стоперан reduces the exposure of co-administered Saquinavir by approximately 50%, highlighting an interaction where Стоперан is the perpetrator.

Mechanism of Action

Targeting Peripheral Opioid Receptors to Slow Motility

This core mechanism involves the active substance acting as an agonist on the mu-opioid receptors located in the Enteric Nervous System (ENS) within the intestinal wall. . This molecular action inhibits the release of excitatory neurotransmitters (like Acetylcholine), which are responsible for smooth muscle contraction. The resulting suppression of propulsive peristalsis prolongs the intestinal transit time of contents through the gut, which is a primary physiological consequence. The drug's action is confined to the periphery because it is actively pumped out of the Central Nervous System by the P-glycoprotein transporter.


Enhancing Fluid Reabsorption and Modulating Secretion

A physiological consequence of the prolonged transit time is the increased duration for the intestinal lining to reabsorb water and electrolytes back into the body. This reabsorptive effect is complemented by a direct anti-secretory action, achieved through secondary receptor effects and the inhibition of the intracellular protein Calmodulin. This mechanism modulates fluid homeostasis by both decreasing secretion and increasing reabsorption, resulting in the adjustment of fluid ratio within the intestinal lumen.


️ Mechanistic Constraints in Certain Physiological States

While modulating hyperactive motility, the mechanism is physiologically constrained when dealing with severe toxin-mediated hypersecretion, where massive fluid output overrides the adjustment in transit time. Additionally, the anti-motility effect is regionally dependent, showing a more pronounced influence on the smooth muscle activity of the lower digestive tract compared to the upper sections.

Dosage and Administration Information

How to Use Стоперан: Administration Guidelines

Administration of Стоперан (Loperamide hydrochloride) is based on specific patterns that focus on symptom response rather than fixed schedules. The medicine is approved for use via the oral route across all available forms, including capsules and oral solution.


Dosing and Scheduling Principles

Feature Instruction / Entity
Route of Administration Oral
Adult Initial Dose 4 mg (one time administration)
Subsequent Dosing 2 mg after each subsequent unformed stool
Maximum Daily Limit 8 mg (over-the-counter) or 16 mg (prescription), not to be exceeded

Use Patterns and Procedural Rules

Frequency Pattern

Following the initial dose, administration operates on an as-needed, condition-dependent basis; doses are administered in response to a physiological event (unformed stool), making the schedule flexible but constrained by the maximum dose.

Administration Specifics

The capsule form must be swallowed whole without crushing or chewing. For the oral liquid, the bottle must be shaken well before use to ensure proper content distribution. The administration protocol includes maintaining appropriate fluid and electrolyte replacement.

Time-Limited Use Assessment

The usage protocol mandates specific time restrictions. For acute conditions, administration is discontinued if no clinical improvement is observed within 48 hours. For children under 2 years of age, the medication is not recommended. No specific dosage adjustment is typically required for older adults or individuals with renal impairment.

This procedural structure details the standardized approach to using the medicine, defining limits and conditions for proper intake.

Recent Clinical Evidence

Стоперан: Recent Clinical Evidence

Evidence for Managing Acute Diarrheal Symptoms

The research base for Стоперан primarily consists of systematic reviews and meta-analyses aggregating findings from numerous short-term, randomized controlled trials (RCTs). These investigations compared the medicine to a placebo to examine outcomes related to physical discomfort, specifically the time to the last measured symptom change and the change in the daily count of loose bowel movements. Findings reported in the studies describe patterns where measured changes were observed at earlier time points in the treated populations compared to placebo. This research contributes to understanding short-term changes in patients experiencing acute episodes.


Evidence for Chronic Diarrhea and Functional Control

Стоперан was also studied for its evaluation in the context of chronic diarrhea in adults. This research includes specialized RCTs and observational studies focused on different outcomes reflecting daily functioning, such as the change in the frequency of loose bowel movements and the volume of ileostomy discharge. Reported data described patterns related to lower functional measurements (volume and count) in the observed populations. However, compared to acute uses, comparative evidence is lacking for managing chronic symptoms over extended periods.


Research Gaps and Areas of Uncertainty

A key research limitation is the focus on short follow-up durations for acute episodes. Long-term effects are not fully established regarding the durability of observed changes in chronic use. For special populations, the medicine was evaluated in some cohorts of children between 2 and 12 years, but data for certain groups remain insufficient (e.g., children under 3 years). The findings describe group patterns, not personal outcomes, and certainty remains low in predicting individual response across the varied causes of diarrhea.

Key Studies & References

  1. Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-Analysis (PLOS Medicine)
  2. Loperamide vs. Placebo's Effect on Ileostomy Output: a Clinical Randomized Blinded Cross-over Study (ClinicalTrials.gov)
  3. Label: LOPERAMIDE HYDROCHLORIDE tablet (FDA/DailyMed)
  4. Antimotility Agents for the Treatment of Acute Noninfectious Diarrhea in Critically Ill Patients - Practice Management Guideline (EAST)

Frequently Asked Questions (FAQ)

Common questions about Стоперан (FAQ)


Q: How quickly can someone expect Стоперан to start working?

Clinical information compiled by governmental bodies suggests that the onset of action may be observed at an early time point. Official data indicates this time may start within 30 minutes after the medicine is administered.


Q: Is it normal to feel a little dizzy after taking Стоперан?

Official safety information classifies dizziness as a common adverse reaction reported in patients using the medicine. Common side effects are those recognized during clinical observations. Therefore, experiencing dizziness is a documented possibility in the product's regulatory profile.


Q: How long does the effect of one dose of Стоперан typically last?

The duration of the effect has been described in clinical information as potentially lasting for several hours. Official dosing guidelines emphasize administering the medicine on an as-needed basis in response to symptoms, rather than on a fixed schedule.


Q: Can Стоперан be taken at the same time as cold medicine?

Regulatory documents describe a potential interaction risk when combining this medicine with other drugs that cause Central Nervous System (CNS) depression. Since some cold and flu medicines contain sedating ingredients, combining them may increase the risk of profound sedation or other CNS effects.


Q: Can someone use Стоперан if they have a history of irritable bowel syndrome (IBS)?

Official guidance from regulatory bodies notes that the medicine may be used to manage short-term diarrhea associated with Irritable Bowel Syndrome (IBS) in adults. Regulatory documents indicate its use for IBS-related diarrhea is established for patients who have received a prior diagnosis from a healthcare professional.


Q: Is the research evidence for Стоперан considered high-quality?

The clinical evidence base consists mainly of short-term, randomized controlled trials (RCTs) and systematic reviews. Official summaries note a key research limitation in the focus on short follow-up durations for acute use, and indicate low certainty remains in predicting an individual's specific response.


Q: Can men and women use Стоперан in the same way?

Regulatory documents define standard use and eligibility based primarily on age and the presence of contraindicated medical conditions. There are no specific differences in the administration instructions noted for sex in the official prescribing information.


Q: Are there any known interactions between Стоперан and herbal supplements?

Official warnings advise against combining the medicine with other pharmacological drugs or herbal products that are known to have an effect on the heart rhythm. This caution is related to the potential for additive effects on the heart rhythm.


Q: Can Стоперан be taken alongside vitamins or mineral supplements?

Regulatory patient information stresses the general importance of informing a healthcare provider of all medications, vitamins, and supplements being used. This ensures the healthcare provider is aware of all substances being used.


Q: Does taking Стоперан affect the ability to drive or operate machinery?

Official patient warnings advise against driving or operating machinery if side effects such as dizziness, tiredness, or somnolence (drowsiness) are experienced. This is a standard caution associated with CNS side effects.


Q: What kind of studies support the claims made about Стоперан?

The claims are supported by clinical findings aggregated from short-term, randomized controlled trials (RCTs). This data has been summarized into systematic reviews and meta-analyses to establish the medicine's symptomatic relief capabilities.


Q: Does Стоперан affect the absorption of nutrients from food?

The medicine’s mechanism prolongs the intestinal transit time, which allows for increased reabsorption of water and electrolytes. This fundamental physiological adjustment is relevant to the bowel’s overall function in absorbing nutrients from consumed food.


Q: Can people with liver problems use Стоперан?

Regulatory documents advise that the medicine should be used with caution in patients with hepatic impairment (liver problems). This is due to a potential increase in systemic exposure, which may raise the risk of Central Nervous System (CNS) effects.


Q: Is Стоперан the same as Imodium, or are they different?

Стоперан is the active ingredient, Loperamide hydrochloride, which is found in many different products. It is sold under various brand names by different manufacturers around the world, including the common brand name Imodium.


Q: Is Стоперан available over the counter?

The medicine is generally available for purchase over-the-counter (OTC) for adults and adolescents 12 years and older for short-term use. For certain chronic or long-term applications, it may also be available by prescription.


Q: Does Стоперан have a generic version?

Yes, the active ingredient Loperamide hydrochloride is available from multiple manufacturers. It is available as a generic version in addition to various brand-name products.


Q: Are there any specific foods or drinks that should be avoided when using Стоперан?

Official patient information advises avoiding alcohol during use due to potential drug interactions. Otherwise, general guidance is that individuals can usually eat and drink normally while taking the medicine.


Q: What should be done if a dose of Стоперан is missed?

Regulatory patient information states that a missed dose may be taken if symptoms occur, returning to the condition-dependent dosing schedule (taken after each unformed stool). A double dose should not be taken to make up for a missed one.


Q: Can Стоперан be crushed or split for easier swallowing?

Official administration specifics indicate that the capsule form must be swallowed whole without crushing or chewing. For patients who have difficulty swallowing tablets, the oral liquid formulation is typically available as an alternative.


Q: Does Стоперан contain any common allergens like gluten or lactose?

The inactive ingredients (excipients) used in some formulations of the medicine may include lactose monohydrate. Individuals with specific allergies or sensitivities should always check the full list of ingredients for their specific product formulation.


Q: Can Стоперан be used to prevent diarrhea before traveling?

The medicine is indicated for the symptomatic relief of diarrhea. It is not officially indicated for preventive (prophylactic) use against diarrhea before or during travel.


Q: Does the time of day when Стоперан is taken matter?

The official administration schedule is condition-dependent, meaning doses are taken only in response to a physiological event (an unformed stool). Therefore, the time of day is flexible and is dictated by the severity of the symptoms, not a fixed daily clock.


Q: Are there different brand names for the same active ingredient as Стоперан?

Yes, the active ingredient Loperamide hydrochloride is marketed under many different brand names by various manufacturers around the world. These products contain the same active medicinal substance.


Q: Is there a risk of masking a serious infection by using Стоперан?

Official risk summaries note a potential risk where prolonged use of the medicine may mask an underlying condition or infection that requires specific medical attention. This potential risk is related to why the medicine is contraindicated in certain infectious conditions.


Q: Is there any difference in how Стоперан works in different age groups?

While the core mechanism of action is the same across populations, regulatory information notes that there is greater variability of response observed in pediatric patients. This variability is particularly noted in pediatric patients.

How should Стоперан be stored and disposed of?

How to Store and Dispose of Стоперан (Loperamide)

The storage and disposal of Стоперан must strictly follow the official conditions documented in regulatory labeling to maintain product stability and safety.

Storage Requirements

The product must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The label requires the product to be protected from light and moisture, and it must be kept in its original container with the lid tightly closed to prevent contamination and maintain stability. The official instruction is to keep this medication out of the sight and reach of children and avoid storing it in environments with excessive heat or moisture.

Disposal Instructions

Unused or expired Стоперан should generally not be flushed down the toilet or poured into a drain. Disposal must be conducted according to local regulations, often by using an authorized drug take-back program or following specific instructions provided by a pharmacist to ensure proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Стоперан found in:

A-Z Index: